BioNxt Solutions Provides Bi-Weekly MCTO Status Report
VANCOUVER, BC / ACCESS Newswire / June 12, 2025 / BioNxt Solutions Inc. ('BioNxt' or the 'Company') (CSE:BNXT)(OTC PINK:BNXTF)(FSE:4XT), announces that, further to its news release dated May 1, 2025 (the 'Default Announcement'), the Company's principal regulator, the British Columbia Securities Commission (the 'BCSC') granted a management cease trade order (the 'MCTO') on May 1, 2025, under National Policy 12-203 Management Cease Trade Orders ('NP 12-203").
Pursuant to the MCTO, the Chief Executive Officer and the Chief Financial Officer may not trade in securities of the Company until such time as the Company files its annual audited financial statements for the year ended December 31, 2024, including the related management's discussion and analysis, and CEO and CFO certifications on or before June 30, 2025 (collectively the 'Required Documents') and the Executive Director of the BCSC revokes the MCTO. The MCTO does not affect the ability of shareholders to trade their securities.
The Company's staff are working diligently with its auditors and the Company anticipates that it will be in a position to file the Required Documents by June 30, 2025. All previously outstanding audit materials related to the Company's German subsidiaries are now in-hand and the consolidations model is complete. Draft financials have been prepared and provided to the Company's audit firm.
The Company's Board of Directors and management confirm that they are working expeditiously to file the Required Documents and confirm that since the Company's Default Announcement:
Until the Required Documents have been filed, the Company intends to continue to satisfy the provisions of the Alternative Information Guidelines specified in NP 12-203 by issuing these bi-weekly default status reports in the form of further press releases for so long as the Company remains in default of the Required Documents filing requirement.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co‐Founder, CEO and Director
Email: [email protected]
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding 'Forward‐Looking' Information
This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'anticipates,' 'believes,' 'estimates,' 'may,' 'could,' 'will,' 'plans,' and similar expressions. These statements relate to future events or future performance, including, but not limited to, statements regarding the anticipated timing for filing the Required Documents, the Company's ability to remedy its filing default, the expected revocation of the MCTO, and the Company's continued compliance with National Policy 12-203 Management Cease Trade Orders ('NP 12-203"). Forward-looking statements are based on the Company's current expectations, beliefs, and assumptions, including assumptions regarding the timely completion of the audit process, the ability of the Company and its auditors to meet required filing deadlines, the accuracy of management's estimates and expectations, regulatory approvals, and market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Factors that could cause actual results to differ materially include, but are not limited to: delays in the audit process; the Company's inability to file the Required Documents within the anticipated timeframe; regulatory or compliance issues; changes in financial reporting or disclosure standards; unanticipated requests for additional information from auditors or regulators; and other unforeseen financial, operational, or regulatory developments. Additional risk factors are outlined in the Company's public filings available on SEDAR+ ( www.sedarplus.ca ). The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements, as actual results may differ materially from expectations.
SOURCE: BioNxt Solutions Inc.
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
UBS Says Future Estimates for Freshpet, Inc. (FRPT) Are Too High
Freshpet, Inc. (NASDAQ:FRPT) remains one of the 7 best future food stocks to buy according to analysts, reflecting its strong growth potential in the premium pet food market. Amy Rene/ Citing concerns about overly optimistic growth expectations, UBS gave a 'Sell' rating to Freshpet stock with a $65 price target on June 16, 2025. The analyst called out the company's top and bottom-line estimates as too high, which are in the mid-to-high teens growth range, as implied by its pricing. The analyst believes this will lead to valuation contraction. Based on the company's guidance for 2025, it projects 15%-18% revenue growth, which would result in $190-$210 million in adjusted EBITDA. Meanwhile, Freshpet, Inc. (NASDAQ:FRPT) surpassed analyst estimates in Q1 2025, where it reported an 18% YoY increase in sales and 45.7% growth in its adjusted gross margin. Thus, Freshpet, Inc.'s (NASDAQ:FRPT) short-term performance is one to keep an eye on. The company is a manufacturer and distributor of fresh food and treats for dogs and cats in the U.S., Canada, and Europe. It is one of the best future food stocks. While we acknowledge the potential of FRPT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Marketing Stocks to Buy Right Now and . Disclosure: None.
Yahoo
4 hours ago
- Yahoo
UBS Says Future Estimates for Freshpet, Inc. (FRPT) Are Too High
Freshpet, Inc. (NASDAQ:FRPT) remains one of the 7 best future food stocks to buy according to analysts, reflecting its strong growth potential in the premium pet food market. Amy Rene/ Citing concerns about overly optimistic growth expectations, UBS gave a 'Sell' rating to Freshpet stock with a $65 price target on June 16, 2025. The analyst called out the company's top and bottom-line estimates as too high, which are in the mid-to-high teens growth range, as implied by its pricing. The analyst believes this will lead to valuation contraction. Based on the company's guidance for 2025, it projects 15%-18% revenue growth, which would result in $190-$210 million in adjusted EBITDA. Meanwhile, Freshpet, Inc. (NASDAQ:FRPT) surpassed analyst estimates in Q1 2025, where it reported an 18% YoY increase in sales and 45.7% growth in its adjusted gross margin. Thus, Freshpet, Inc.'s (NASDAQ:FRPT) short-term performance is one to keep an eye on. The company is a manufacturer and distributor of fresh food and treats for dogs and cats in the U.S., Canada, and Europe. It is one of the best future food stocks. While we acknowledge the potential of FRPT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Marketing Stocks to Buy Right Now and . Disclosure: None. 登入存取你的投資組合
Yahoo
5 hours ago
- Yahoo
CHAUDHRI: How businesses can stay ahead of workplace issues
My origin story as a business owner started in 2021 when I launched my own firm – Workly Law. With some savings I created a website, registered a business number and opened a trust account. I rented a very small private office in a co-working space. I was also a very new mom operating on my then seven-month-old child's erratic sleep schedule. Then, I hired my first employee; a sharp lawyer, newly called to the bar. Even though I was an employment lawyer myself, I had a lot to learn about how to grow my business while also creating a workplace that could retain talent and grow. I drafted my own employment contracts and then considered my own workplace policies. How would I manage sick time, remote work requests and vacations? Also, there were a slew of mandatory policies I had to roll out just to be legally compliant. CHAUDHRI: Terminations can be hard to fight – even for the powerful CHAUDHRI: Multinational corporations beware – one size does not fit all CHAUDHRI: Alleging cause requires hard evidence I recall this period as one of mild frenzy. We had to grow our footprint in the marketplace, retain new clients and hire lawyers. Any business owner will agree that creating a good workplace is not something that springs up organically. It's more like a finicky rose bush. It needs watering, tending to, and sometimes a little pruning. Do this with discipline and something starts to blossom. As time goes on, I have supported more and more employers to help navigate the legal challenges in their workplaces. This year, with my team, we created a 2025 employer guide. Our guide breaks down key employer obligations like the following: Changes to the Employment Standards Act – On a very regular basis, the Ontario Employment Standards Act is updated with new legal obligations that employers are required to comply with on an immediate basis. Our guide sets a framework for what employers need to do to be legally compliant in 2025. The right way to manage a sick leave – The law has changed on what documentation employers can seek to support an employee medical leave. We have set out best practices for employers to follow. The legal implications of remote work – Employers are increasingly interested in how to return employees to the office while retaining as much of your workforce as possible. Key clauses you need in every employment agreement – From strong termination clauses to confidentiality agreements, our guide lays out what every employer should consider when hiring a new employee. It has been a challenge but also a thrilling experience to put what I've learned as an employment lawyer and a business owner into a document that can help other businesses. Like anything, it will evolve as I learn more and as the world of employment law evolves. Being a business owner is a high privilege, but it is one that is steeped obligation. Business owners are the guardians of the livelihoods of their workers. We have to try, as best we can, to get it right. Have a workplace problem? Maybe I can help! Email me at sunira@ and your question may be featured in a future column. The content of this article is general information only and is not legal advice.
